Arovella Therapeutics Ltd Total Assets
Arovella Therapeutics Ltd total assets. Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) holds total assets worth AU$20.25 Million AUD (≈ $14.33 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Arovella Therapeutics Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Arovella Therapeutics Ltd (2001–2025)
Total assets of Arovella Therapeutics Ltd from 2001 to 2025. This chart illustrates how Arovella Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See ALA live share price for real-time trading data and today's change.
Arovella Therapeutics Ltd - Asset Composition Analysis
Arovella Therapeutics Ltd Total Assets Breakdown (June 2025)
Arovella Therapeutics Ltd total assets breakdown as of June 2025. Arovella Therapeutics Ltd's total assets of AU$20.25 Million consist of 98.0% current assets and 2.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$20.88 Million | 96.7% |
| Accounts Receivable | AU$0.00 | 0.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$430.57K | 2.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Arovella Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Arovella Therapeutics Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arovella Therapeutics Ltd's current assets represent 98.0% of total assets in 2025, an increase from 71.0% in 2001.
- Cash Position: Cash and equivalents constituted 96.7% of total assets in 2025, up from 70.7% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 2001.
- Asset Diversification: The largest asset category is cash and equivalents at 96.7% of total assets.
Arovella Therapeutics Ltd Competitors by Total Assets
Key competitors of Arovella Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Arovella Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.36 | 11.24 | 3.79 |
| Quick Ratio | 15.36 | 11.24 | 3.78 |
| Cash Ratio | 15.00 | 10.82 | 3.60 |
| Working Capital | AU$18.55 Million | AU$11.12 Million | AU$4.24 Million |
Arovella Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Arovella Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.86 |
| Latest Market Cap to Assets Ratio | 1.98 |
| Asset Growth Rate (YoY) | 62.6% |
| Total Assets | AU$21.60 Million |
| Market Capitalization | $42.76 Million USD |
Valuation Analysis
Above Book Valuation: The market values Arovella Therapeutics Ltd's assets above their book value (1.98x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Arovella Therapeutics Ltd's assets grew by 62.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Arovella Therapeutics Ltd (2001–2025)
The table below shows the annual total assets of Arovella Therapeutics Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$21.60 Million ≈ $15.28 Million |
+62.60% |
| 2024-06-30 | AU$13.28 Million ≈ $9.40 Million |
+142.82% |
| 2023-06-30 | AU$5.47 Million ≈ $3.87 Million |
-40.61% |
| 2022-06-30 | AU$9.21 Million ≈ $6.52 Million |
-13.80% |
| 2021-06-30 | AU$10.69 Million ≈ $7.56 Million |
+59.33% |
| 2020-06-30 | AU$6.71 Million ≈ $4.75 Million |
-58.73% |
| 2019-06-30 | AU$16.25 Million ≈ $11.50 Million |
-2.34% |
| 2018-06-30 | AU$16.64 Million ≈ $11.78 Million |
-16.85% |
| 2017-06-30 | AU$20.02 Million ≈ $14.16 Million |
+2.56% |
| 2016-06-30 | AU$19.52 Million ≈ $13.81 Million |
-14.48% |
| 2015-06-30 | AU$22.82 Million ≈ $16.15 Million |
+12.16% |
| 2014-06-30 | AU$20.35 Million ≈ $14.40 Million |
+89.65% |
| 2013-06-30 | AU$10.73 Million ≈ $7.59 Million |
+9.99% |
| 2012-06-30 | AU$9.75 Million ≈ $6.90 Million |
-27.88% |
| 2011-06-30 | AU$13.53 Million ≈ $9.57 Million |
+13.64% |
| 2010-06-30 | AU$11.90 Million ≈ $8.42 Million |
-28.35% |
| 2009-06-30 | AU$16.61 Million ≈ $11.75 Million |
+3.41% |
| 2008-06-30 | AU$16.06 Million ≈ $11.37 Million |
-23.50% |
| 2007-06-30 | AU$21.00 Million ≈ $14.86 Million |
+26.27% |
| 2006-06-30 | AU$16.63 Million ≈ $11.77 Million |
+11.22% |
| 2005-06-30 | AU$14.95 Million ≈ $10.58 Million |
-7.11% |
| 2004-06-30 | AU$16.10 Million ≈ $11.39 Million |
+245.95% |
| 2003-06-30 | AU$4.65 Million ≈ $3.29 Million |
+47.97% |
| 2002-06-30 | AU$3.14 Million ≈ $2.22 Million |
-48.60% |
| 2001-06-30 | AU$6.12 Million ≈ $4.33 Million |
-- |
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more